

Lisbon 2023, at the edge of Europe and Science Annual EUFEPS Conference, May 31st – June 2nd, 2023 in Lisbon, Portugal

Pre-Conference Workshop "History of Pharmacy"

	May 31 st
09:00-12.00	Pre-Conference Workshop "History of Pharmacy"
	Moderation: António Almeida
09:00 – 09:15	Welcome
09:15 – 10:00	Maria Guilherme Semedo, Ana Leonor Pereira, João Rui Pita Cinchona bark and quinine in the Portuguese official pharmacopoeias (1794-2001)
10:00 – 10:45	Toine Peters, The Dutch cinchona and quinine monopoly (1900-1950), presented by Bert Leufkens
10:45 – 11:15	Coffee break
11:15 – 12:00	Joao Neto, Director of Pharmacy Museum of Lisbon, Time capsule of Science

Main Conference Program

	May 31 st		
12.30- 13.00	Welcome coffee		
13.00- 13.15	Opening of the EUFEPS ANNUAL CONFERENCE 2023, Prof. Dr. Joao Lopes, Conference Chair Prof. Dr. Maria Blanco-Prieto, EUFEPS President Prof. Dr. Beatriz da Silva Lima, Dean of the Faculty of Pharmacy, University of Lisbon EUFEPS Presidential Distinction Award		
13.15- 14.00	PL1, Anke - Hilse Maitland	l-van der Zee, On the Edge of Science, On the Edge Chair: Anna Birna Almarsdóttir	of Precision Medicine
14.00- 14.45	PL2, Patrick Couvreur, Nanomedicines for the treatment of cancer and neurodegenerative diseases Chair: Maria Blanco-Prieto		
14.45- 15.15		Coffee break	
		Invited lectures, parallel sessions I	
	Session 1	Session 2	Session 3
15.15- 16.45	Expanding the role of nano drug delivery system in an evolving scenario for global health— EUFEPS Network Nanomedicine Chair: Maria Blanco-Prieto / Fabio Sonvico	MedChem – EFMC-Innovative approaches for sustainable Drug Discovery Chair: Gianluca Sbardella	Lipid based drug delivery – Slovenian Pharmaceutical Society Chair: Mirjana Gašperlin / Alenka Zvonar Pobirk
15.15- 15.45	Giuseppe De Rosa Lipid self-assembling nanoparticles to foster RNA- based therapies	Antimo Gioiello Multicomponent flow reactions: enabling tools for sustainable medicinal chemistry	Alenka Zvonar Pobirk "Lipid based systems for oral delivery of poorly water soluble drugs and approaches for their solidification"

15.45-	Dagmar Fischer	Kevin Lam			Katarina Bolko Seljak
16.15	From biofilms and hen's eggs:	Electrosynthesis: Your Chemistry Got Potential		emistry Got Potential	Improving drug solubility in novel dosage
	Nano-based drug delivery systems for infection and				forms with SMEDDS
	inflammation				
16.15-	Tomáš Etrych	Sofia Lisina			Jose Catita
16.30	pH-responsive Polymer Nanomedicines for			g fluorimetry as a rapid	Relevance of solid state characterization in
	Photodynamic Therapy and Tumor Imaging	stability assess			the pharmaceutical industry
		nanoformulation	•	ins.	
16.30-	Héctor Rilo-Alvarez	Edorta Santos-			Seval Olgac
16.45	mRNA Activated Matrices as a System for Articular	•		rtalized human hair	Screening and assessment of excipients for
	Cartilage Regeneration		•	mal stromal cell (i-HF-	nanoemulsion formulations of interleukin-2
		scalable secret		e production of	with computational studies
		Scalable secret	ome		
16:45-	Flash presentations (5 min each)				
17:45		Modera	tor: Antón	o Almeida	
1	Seoyoung Park, IPT012 intravitreal implant inhibi		6	Sara Gutierrez-Gu	tierrez, Anionic polyphosphazenes as gene
	neovascularization through promotion of pathoger	ic β-catenin			transport enhancers
	degradation				
2	Joana Pinto-da-Silva, Microencapsulation of bacter		7		n trial-and-error to genetic algorithms for the
_	spray-drying: microparticle characterisation and an	· · · ·			croparticles. A methodological revolution
3	Ágnes Rusznyák, Formulation and investigation of	, , , , , , , , , , , , , , , , , , , ,			pment and characterization of a polymeric film
	polymer-based siRNA delivery systems	5		for ocular controlled re	elease of micelles loaded with neuroprotective
4	Marine Devere Milley Nevel substrate veduction the			Dawbara Harlah Ciro	drugs
4	Marina Beraza-Millor, Novel substrate reduction the siRNA golden lipid nanoparticles for Fabry D		9	Barbara Herlah , Simulation-based optimization of 4,6-substituted-1,3,5-Triazin-2(1H)-Ones as catalytic inhibitors of the human DNA	
	Siniva golden lipid hanoparticles for Fabry D	isease		1,3,3-11182111-2(111)-0	Topoisomerase IIA
5	Sebastian Polak, Virtual Bioequivalence assessment	t of ropinirole			. opensomerase m.
	prolonged release tablets – case study discu	•			
17.45-			ded Poste	r Tour	
19.00					
18.30-		We	lcome Rec	eption	
22.00					

	June 1 st	
08.00- 08.30	Welcome coffee	
8.30- 9.15	PL3 Thomas Sauer, Pioneering technology platforms enable next generation Biologics Chair: Dieter Steinhilber	
9.15- 10.00	PL4 Staffan Folestad, Supplying the Future - Pharma Manufacturing Innovation and Unified Approaches to Personalized Medicine Chair: Fabio Sonvico	
10.00- 10.30	Со	ffee break
	Paral	lel sessions II
10.30-	Session 4	Session 5
12.00	Particle design – EUFEPS - QbD & PAT Network Chair: Jukka Rantanen / Joao Lopes	EurSci4Health: where to go? Chair: Bert Leufkens
	10.30 – 10.55 Ruud van Ommen Atomic layer deposition (ALD) for particle design 10.55 – 11.20 Eftychios (Efty) Hadjittofis Using a morphological population balance to develop a model-driven QbD approach for crystallisation processes 11.20 – 11.30 Lucia Martin-Banderas VCAM-1-targeted nanosystems enhance cannabinoid anti-atherogenic properties	In 2019 EUFEPS initiated the EurSci4Health platform with the objective to advise on scientific policies for health and safety, within European institutions, in order to facilitate the integrated development, regulation and use of diagnostics, therapeutics and other health technologies. The platform aimed to umbrella various scientific societies or federations of societies, and to liaise intensively with other groups (patients, industry, NGOs, other European platforms, etc.). The question of how we as scientists can engage and influence agendas on a European level, is about prioritizing of topics and taking a long view. Research agendas and funding mechanisms work in cycles of (many) years. 'Brussels' looks as a tennis ball launcher constantly sending new policy and/or strategy plans, ideas, consultations, etc. To hit back on time and with success means careful, timely and smart manoeuvring. There is always a WHAT (priority topics/needs) and a HOW (methods of dialogue/intervention) question involved. The proposed panel will reflect on the WHAT and HOW questions from their own background and experiences. All panellists have an extensive background in working in and around the 'Brussels' space.

11.30 – 11.40 Ana Rita Resus	Moderator: Hubert Leufkens, Utrecht University, the Netherlands
Improving the effectiveness of ocular delivery systems using natural	
deep eutectic solvents	1. Mareike Lutz, Chalmers University of Technology, Gothenburg, Sweden
11.40 – 12.00 Discussion and Q&A	2. Rui Moreira, University of Lisbon, President European Federation for
	Medicinal Chemistry and Chemical Biology, Portugal
	3. Jon de Vlieger, Lygature, Utrecht, the Netherlands
	4. Afonso Duarte, national contact point and national delegate for health,
	member of the IHI States representatives group, Agency for Clinical Research
	and Biomedical Innovation, Lisbon, Portugal

	Parallel sessions III				
	Session 6 Session 7 Session 8a				
12.00- 13.30	Pharmacogenomics at the Tipping Point – EUFEPS EPRIN Network Chair: Jesse Swen	New drug Formulations for precision medicine – Spanish Pharmaceutical Society Chair: Marcos Garcia Fuente / María Blanco- Prieto	Translating Science: Bench to Bedside – Portuguese Pharmaceutical Society Chair: Joao Lopes / Helena Florindo		
12.00- 12.30	12:00 – 12:45 Caroline Samer The effect of inflammation on CYP450 activity measured by the Geneva phenotyping	Stefaan De Smedt Beyond nucleic acids as vaccines: curing ocular diseases with nucleic acids?	Paolo Cesare A MEA-based microphysiological toolbox for in vitro modelling of neuronal disorders		
12.30- 13.00	cocktail	12.30 – 12.50 Guojun Xiong Strategies for enhancing the chemotherapeutic effect of paclitaxel in triple negative breast cancer model`sf	Ronit Satchi-Fainaro 3D-Bioprinted cancer models for target discovery, drug development, and personalized therapy		
13.00- 13.15	12:45 – 13:30 Jesse J. Swen Results of the Ubiquitous Pharmacogenomics project	12.50 – 13.10 Elisa Garbayo Self-assembled squalene-adenosine nanoparticles for the treatment of cardiac ischemia-reperfusion injury	Mehtap Saydam A single-dose, open label, randomized, two period, cross-over, pilot bioequivalence study of a BCS class III drug: Tenofovir alafenamide film coated tablet		
13.15- 13.30		13.10 – 13.30 Matilde Durán-Lobato	Teresa Leonardo Alves		

	A targeted nanomedicine for the treatment of	Impact of TTS reports associated with Vaxzevria
	venous thromboembolism, in vitro and in vivo	and Jcovden on national COVID-19 vaccination
	evaluation	policies

13.30- 14.30	Lunch break Workshop: PubPharm: The freely accessible search platform for pharmacy-specific literature and information resources	
14:30- 15.15		piosensors for label-free and real-time multiplexed analysis a Garbayo Atienza
15.15- 16.00	PL6 Rogério Gaspar, WHO role in public health emerg	gencies: bringing together science, regulation and health care r: Joao Lopes
16.00- 16.30		offee break
	Paral	lel sessions IV
	Session 8b	Session 9
16.30- 18.00	Translating Science: Bench to Bedside – Portuguese Pharmaceutical Society Chair: Joao Lopes / António Almeida	Strategies for the preservation of effective antibiotics – the One Health Concept in application– EUFEPS Network Veterinary Medicines Chair: Ivo Schmerold
16.30- 17.00	Felix Carvalho The One Health Concept Under the Perspective of a Toxicologist	Sevda Senel Advanced Formulation Strategies to overcome Antimicrobial Resistance in veterinary and human medicine
17.00- 17.30	Pedro Gouveia Augmented reality and artificial intelligent in breast cancer therapy	I.M. (Inge) van Geijlswijk How to ensure the availability of effective antimicrobials?
17.30- 17.45	Fabiola Guareschi Cyclosporine A micellar nasal spray exhibits a promising antiviral activity against SARS-CoV-2	Lucia Pappalardo Novel research in diagnosis and treatment of avian respiratory fungal disease in falcon patients
17.45- 18.00	Marcos Garcia Fuentes Peptide/polymer hybrid nanoplatforms as immunostimulants against cancer	
19.30	Confe	erence dinner

	June 2 nd			
08.00- 08.30	Welcome coffee			
8.30-		Round Table / Interview		
9.30		"Emerging therapies: regulatory perspective"		
	Mo	derator: Margarida Sousa, Journalist, CNN Portugal		
		Panel:		
	1. Rogério Sá	Gaspar (WHO, Regulation and Pre-qualification De	partment)	
		2. Hubert Leufkens (Utrecht University)		
	3. Alexandre Guedes Silv	va (SPEM - President of the Portuguese Association o	of Multiple Sclerosis)	
		4. Catarina Silva, (Vice-President of EPSA)		
		Parallel sessions V		
	Session 10	Session 11	Session 12	
	Regulation of orphan medicinal products: a	Drug delivery to Skin: Local and Systemic	Tailoring clinical pharmacotherapy to	
09.30-	strong learning device for regulatory science –	applications – Turkish Pharmaceutical Society	patients' needs – Danish Pharmaceutical	
11.00	EUFEPS Network Regulatory Science	Chair: Selma Sahin / Zeynep Teksin	Society, FIGON and Portuguese	
11.00	Chair: Hubert Leufkens / Carla Torre		Pharmaceutical Society	
			Chair: Anna Birna Almarsdóttir / Teresa	
			Alves	
09.30-	Joao Rocha	Sevgi Güngör	09.35 – 10.00 Ana Mirco, Joao Pinto	
10.00	Two decades of of orphan drug development in	Current approaches and Challenges in In vitro	New technologies to tailor pharmacotherapy	
	Europe: where are we?	Release and Permeation Tests for Topical Semi-		
	Solid Products			
10.00-	Enrico Costa	Margarida Miranda	10.00 – 10.25 Charlotte Vermehren	
10.30	The global impact of orphan drug legislations	Tackling formulation complexity in	Deprescribing as an approach to tailor	
		bioequivalence assessment of topical generic	pharmacotherapy	
	products			
10.30-	Lourens Bloem	Luca Giulio	10.25 – 10.50 Ema Paulino	
10.45	Orphan medicinal products as learning device for	Development of Innovative Formulations for the	Testing for COVID-19: Involvement of	
	regulatory science	Topical Delivery of Methotrexate	community pharmacists in Portugal	

10.45- 11.00	Zilke Claessens Impact of expediting regulatory measures on reimbursement of medicines addressing unmet medical needs in Belgium	Ayşe Nur Oktay Pharmacokinetic Evaluation of Cyclodextrin- Based Nanogel Following Dermal Administration on Rats	10.50 – 11.00 Discussion and Wrap-up		
11.00-	medical fleeds in Belgium	Coffee break			
11.30					
11.30-		PhD's Competition			
12.30		Moderator: Luisa Corvo			
		See detailed program below			
		, 3			
		Parallel sessions VI			
	Session 13	Session 14	Session 15		
12.30-	Sustainable/Green pharmacy- Finish	In vitro tools to predict in vivo bioavailability	Radiopharmacy – Austrian <i>Pharmaceutical</i>		
14.00	Pharmaceutical Society	of drugs – EUFEPS BABP Network	Society		
	Chair: Jarkko Ketolainen / Tiina Sikanen.	Chair: Erem Bilensoy / Henning Blume	Chair: Helmut Viernstein / Markus Mitterhauser		
12.30-	Tiina Sikanen	Anne Seidlitz	Markus Mitterhauser		
13.00	Sustainable Drug Development and Use: Toward	Predictive in vitro models for non-oral dosage	You see what you treat, you treat what you see:		
20.00	Better End-of-Life Design	forms	the theranostic concept in nuclear medicine		
13.00-	Lasse Alajärvi	Annette Müllertz	Cecile Philippe		
13.30	Population perspectives on environmental	Oral dosage forms and predictive in vitro tools	Radiopharmaceuticals as a tool for		
	sustainability in the pharmaceutical sector	to assess drug bioavailability	Immunoimaging		
13.30-	Neele Puhlmann	Michał Romański	Eva-Maria Patronas		
13.45	Insights from Pharmaceutical Industry into Drug	Application of a novel PhysioCell® apparatus for	Autoradiography on deparaffinised tissue		
	Discovery & Development: Opportunities to	biopredictive dissolution testing of immediate release formulations - a workflow for in vitro-in	sections		
	design greener APIs	vivo modeling			
13.45-	Eride Quarta	Mehtap Saydam	Theresa Balber		
14.00	Biodegradable materials for improving solubility	In-vitro dissolution, cytotoxicity, in-vitro cell	Investigation of [18F]FDHT binding sites at the		
	and oral absorption of carbamazepine for an eco-	culture and in-vivo pharmacokinetic evaluation	cellular level and during prostate cancer		
	sustainable approach	of solid dosage formulation containing a water-	progression		
		insoluble orphan drug			
14.00-		Awards and Closing ceremony			
14.30					

-EJPS Best Paper Award
- Poster Awards
- EUFEPS WIPS Awards
- Pearls of Bioequivalence Award

EUFEPS PhD Students Competition 2023

June 2, 2023 from 11:30 - 12:30 WEST in Lisbon, Portugal

Moderator: Luisa Corvo

Jury: Ana Grenha (University of Algarve). Dieter Steinhilber (Goethe University Frankfurt) and Thomas Sauer (Sanofi Aventis)

11:30 – 11:35	Luisa Corvo, Welcome and short introduction
11:35 – 11:40	Cristina Casadidio (FIGON), Injectable thermosensitive hydrogel for heart regeneration
11:40 – 11:45	Sipos Bence (Hungary), Meeting patient and regulatory expectations in the early development stages of polymeric nanocarriers
11:45 – 11:50	Souhaila El Moukhtari (Spain), Nanomedicines for the treatment of pediatric neuroblastoma
11:50 – 11:55	Shaquib Rahman Ansari (Sweden), A quality-by-design approach to engineer superparamagnetic nanoparticles for hyperthermia therapy
11:55 – 12:00	Honey Bokharaie (Finland), Proteolytic activation of VEGF-C and its diversity in major clades of the animal kingdom

12:00 – 12:05	ČRT DRAGAR (Slovenia), DEVELOPMENT OF NANOFIBERS WITH MAGNETIC NANOPARTICLES FOR BIOMEDICAL APPLICATIONS
12:05 – 12:10	Bárbara Carreira (Portugal), Translational nanotechnology- based cancer nanovaccine to re-educate host immune response against melanoma brain metastases
12:10 – 12:15	Gianluca Bazzoli (Italy), New inhalation drug delivery systems for the treatment of pulmonary fibrosis
12:15 – 12:20	Gülşen Aybar Tural (Turkey), Preparation and Characterization of Microrobot Systems for Active Drug Targeting
12:20 – 12:25	Ioannis Partheniadis (Greece), Hot-melt extrusion using preprocessed feed for the preparation of co-amorphous griseofulvin/amino acid systems